MapLight Therapeutics
MPLT
MapLight Therapeutics (MPLT) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Guggenheim | Initiated Coverage | Neutral | — | Oct 6, 2026 |
| Needham | Maintained | Buy | $43.00 from $45.00 | Aug 31, 2026 |
| UBS | Downgraded | Buy → Neutral | $13.00 from $52.00 | Aug 10, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $26.00 from $45.00 | Jul 28, 2026 |
| Morgan Stanley | Downgraded | Overweight → Equal-Weight | $21.00 from $34.00 | Jul 28, 2026 |
| Canaccord Genuity | Maintained | Buy | $24.00 from $43.00 | Jul 28, 2026 |
| Canaccord Genuity | Maintained | Buy | $43.00 from $35.00 | Jul 24, 2026 |
| BMO Capital | Initiated Coverage | Outperform | $46.00 | Jul 21, 2026 |
| UBS | Maintained | Buy | $52.00 from $48.00 | Jul 21, 2026 |
| Needham | Maintained | Buy | $45.00 from $42.00 | Jul 10, 2026 |
| Raymond James | Initiated Coverage | Strong Buy | $46.00 | Jun 25, 2026 |
| Craig-Hallum | Maintained | Buy | $40.00 from $43.00 | Jun 23, 2026 |
| Needham | Maintained | Buy | $42.00 from $37.00 | Jun 22, 2026 |
| Stifel | Maintained | Buy | $36.00 from $28.00 | Jun 2, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $45.00 | May 28, 2026 |
| UBS | Initiated Coverage | Buy | $48.00 | May 27, 2026 |
| Craig-Hallum | Initiated Coverage | Buy | $43.00 | May 21, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $45.00 | May 4, 2026 |
| Needham | Initiated Coverage | Buy | $37.00 | Apr 8, 2026 |
| TD Cowen | Initiated Coverage | Buy | — | Apr 7, 2026 |
Frequently asked questions
What is the latest analyst rating on MPLT?
On Oct 6, 2026, Guggenheim initiated coverage of MapLight Therapeutics at Neutral.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.